Press release
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investor Alert: Deadline in Lawsuit on August 25, 2025
A Deadline is coming up on August 25, 2025 in the lawsuit for certain investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Investors who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and there are strict and short deadlines running. Deadline: August 25, 2025. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of New the plaintiff alleges on behalf of purchasers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) common shares between June 22, 2023, and June 24, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 22, 2023, and June 24, 2025, the Defendants made false and/or misleading statements and/or failed to disclose that ELEVIDYS posed significant safety risks to patients, that ELEVIDYS trial regimes and protocols failed to detect severe side effects, that the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals, and that as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
Those who purchased shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investor Alert: Deadline in Lawsuit on August 25, 2025 here
News-ID: 4156549 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of Elevance Health, In …
An investigation was announced for current long-term investors in shares of Elevance Health, Inc. (NYSE: ELV) concerning potential breaches of fiduciary duties by certain directors of Elevance Health, Inc.
Investors who are current long term investors in Elevance Health, Inc. (NYSE: ELV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors…
Lawsuit Alert: Investors who lost money with shares of Lockheed Martin Corporati …
An investor, who purchased shares of Lockheed Martin Corporation (NYSE: LMT), filed a lawsuit over alleged violations of Federal Securities Laws by Lockheed Martin Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lockheed Martin Corporation (NYSE: LMT)) have certain options and for certain investors are short and strict deadlines running. Deadline: September 26, 2025. NYSE: LMT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of KinderCare Learning Co …
An investor, who purchased shares of KinderCare Learning Companies, Inc. (NYSE: KLC), filed a lawsuit over alleged violations of Federal Securities Laws by KinderCare Learning Companies, Inc. in connection with certain allegedly false and misleading statements made in connection with KinderCare's October 2024 initial public offering (the "IPO").
Investors who purchased shares of KinderCare Learning Companies, Inc. (NYSE: KLC) have certain options and for certain investors are short and strict deadlines…
Investigation announced for Long-Term Investors in Compass Diversified (NYSE: CO …
An investigation on behalf of current long-term investors in shares of Compass Diversified (NYSE: CODI) concerning potential breaches of fiduciary duties by certain directors and officers of Compass Diversified (NYSE: CODI was announced.
Investors who are current long term investors in Compass Diversified (NYSE: CODI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current…
More Releases for Sarepta
Limb Girdle Muscular Dystrophy Pipeline 2025: MOA, ROA, and Clinical Trial Insig …
Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Limb Girdle Muscular Dystrophy Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.
The Limb Girdle Muscular Dystrophy Pipeline report…
Arrowhead and Sarepta Forge $11.38 Billion Partnership to Advance Neuromuscular …
► Global Gene Therapy Market Poised for Robust Growth
The global gene therapy market is experiencing significant expansion, driven by advancements in genetic research and increasing prevalence of genetic disorders. According to Maximize Market Research, the market was valued at USD 10.03 billion in 2024 and is projected to reach USD 32.89 billion by 2032, growing at a compound annual growth rate (CAGR) of 16% during the forecast period.
► Competitive…
Duchenne Muscular Dystrophy Market Growth, Demand, And Segments to 2033 Sarepta, …
Duchenne Muscular Dystrophy (DMD) is a severe form of muscular dystrophy, characterized by progressive muscle degeneration and weakness, primarily affecting boys due to its X-linked inheritance. It is caused by mutations in the dystrophin gene, which leads to a deficiency of dystrophin, a protein essential for muscle cell stability. The condition typically presents in early childhood, with affected individuals showing difficulty walking, running, and climbing stairs by the age of…
Limb Girdle Muscular Dystrophy Clinical Trials Assessment 2024: FDA Approvals, D …
(Albany, USA) Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Limb Girdle Muscular Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.
The Limb Girdle Muscular Dystrophy Pipeline…
Overview of Global Gene Therapy Market | Biogen, Gilead Sciences, Inc., Sarepta …
Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the Global Gene Therapy Market. This comprehensive report aims to equip businesses with invaluable insights and data, enabling them to make informed decisions and stay one step ahead of the competition.
Access the Comprehensive PDF Market Research Analysis Report Here: https://www.astuteanalytica.com/request-sample/gene-therapy-market
The Global Gene Therapy Market accounted for close to US$ 3.44 billion…
Overview of Global gene therapy market | Sarepta Therapeutics, Inc., Amgen Inc.
Astute Analytica, a leading provider of market research and analysis, released its highly anticipated Market Analysis Report on the global gene therapy market. This comprehensive report aims to equip businesses with invaluable insights and data, enabling them to make informed decisions and stay one step ahead of the competition.
The global gene therapy market accounted for close to US$ 3.44 billion by 2022 and is forecast to see growth at a…
